Spyre Therapeutics, Inc SYRE 深 滬
已收盤 08-07 16:00:00 美东时间
104.91
+1.490
+1.44%
華盛通- 最 高106.67
- 今 開106.01
- 成交量 52.66万股
- 最 低 103.64
- 昨 收 103.42
- 總市值 92.50亿
- 52周最高 108.14
- 市盈率 靜 --
- 換手率 0.60%
- 52周最低 14.505
- 委 比 -98.20%
- 總股本 8817.38万
- 歷史最高 318.75
- 量 比 0.68
- 振 幅 2.93%
- 歷史最低 2.66
- 每 手 1
- 風險率 27.53%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
Wedbush Maintains Outperform on Spyre Therapeutics, Raises Price Target to $130
Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and raises the price target from $100 to $130.
08-05 21:27
Spyre Therapeutics Q2 EPS $(0.36) Beats $(0.73) Estimate
Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.73) by 50.68 percent. This is a 26.53 percent increase over losses of $(0.49) per share from the same period last year.
08-05 04:52
Wolfe Research Downgrades Spyre Therapeutics to Peer Perform
Wolfe Research analyst Andy Chen downgrades Spyre Therapeutics (NASDAQ:SYRE) from Outperform to Peer Perform.
07-29 00:17
美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
Mizuho Maintains Outperform on Spyre Therapeutics, Raises Price Target to $120
Mizuho analyst Joseph Catanzaro maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and raises the price target from $84 to $120.
07-13 18:50
What's Going On With Spyre Therapeutics Stock On Wednesday?
Spyre Therapeutics Inc. (NASDAQ:SYRE) stock plunged more than 12% on Wednesday as investors reacted to large insider stock sales. The stock is up more than 160% year to date and over 450% over the past year. Insider Sales Weigh on Sentiment Fairmount Healthcare Fund II L.P., affiliated with company ...
06-24 23:56
美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
06-24 14:08
